(Press-News.org) The drug combination of ledipasvir and sofosbuvir (trade name Harvoni) has been available since November 2014 for the treatment of chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.
IQWiG found a hint a non-quantifiable added benefit for two out of seven patient groups in total: in an infection with genotype 1 hepatitis C virus (HCV) when previous therapies had been unsuccessful, and when previously untreated patients have not yet developed cirrhosis of the liver. The data showed an advantage in sustained virologic response (SVR): Almost all patients were free of the virus after the Treatment.
Dossier only contained historical comparisons
IQWiG examined the added benefit separately for a total of seven patient groups, which were categorized according to genotype of the virus (1, 3, or 4), stage of the disease and previous treatment.
The drug manufacturer presented no direct comparative studies, but so-called historical comparisons. In a historical comparison, data from different studies, in which at least one of the treatments to be compared was tested, are compared.
At most hint possible
However, these kinds of results are susceptible to bias for several reasons. Conclusions on the (added) benefit can therefore generally only be derived when the effect differences are so large that they cannot be explained by the bias alone ("dramatic effect"). Due to the reduced certainty of conclusions, no more than a hint can be derived from these kinds of data, but no indication or even proof.
Genotype 1: almost all patients were free of the virus after treatment
For three patient groups with genotype 1, the manufacturer conducted a historical comparison from more than 20 studies in total, which showed a dramatic effect in the outcome "SVR": After treatment with ledipasvir and sofosbuvir, the virus was no longer detectable in almost 100% of the patients - treatment-experienced and treatment-naive patients with and without cirrhosis. In contrast, the success rate of the respective comparator therapies was only between nearly 35% and 75%.
The difference between the treatments was so large that an advantage of the new drug combination could be derived from it. It remained unclear, however, how large this difference is exactly because these were only historical comparisons.
It remained unclear how often liver cancer can be prevented
Greater harm in the form of side effects could not be excluded in treatment-naive patients with cirrhosis of the liver, however. IQWiG therefore found a hint of an added benefit only in two of the three genotype 1 groups, namely treatment-experienced and treatment-naive patients without cirrhosis of the liver.
The extent of this added benefit is non-quantifiable, however. It remained unclear in how many patients in whom the virus is no longer detectable liver cancer can actually be prevented.
No added benefit for further patient groups
IQWiG found no added benefit of ledipasvir/sofosbuvir in any of the other four patient groups: The manufacturer dossier either contained no data (HCV genotype 4) or no comparative data (HCV genotype 3 and decompensated cirrhosis of the liver). For patients with genotype 1 HCV who are also infected with HIV, the manufacturer presented comparative data, but these were incomplete.
G-BA decides on the extent of added benefit
This dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information on ledipasvir/sofosbuvir.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
HEIDELBERG, 10 March 2015 - An international group of researchers has shown that a regulatory protein involved in controlling how cancer spreads through the body also influences the fate of stem cells in the intestine of mice. The results, which are published in The EMBO Journal, show that the Snai1 protein plays an important role in deciding the fate of intestinal stem cells and the different functions that these cells can adopt.
"Our results show that Snai1 is a key regulator of crypt base columnar cells, a type of stem cell found in the invaginations or crypts that ...
New research conducted by The University of Manchester has found that GPs' patients can feel alienated by lack of trust, impersonal processes and that this presents problems to improving their safety.
Most research into patient safety focuses on the systems operated by health services. This is particularly focused on hospitals. However, most encounters occur within GP services where relationships between doctor and patient can form a significant part of reaching successful diagnosis and treatment.
The team from the NIHR Greater Manchester Primary Care Patient Safety ...
Study suggests that millions of modern Asian men are descended from 11 ancient leaders, including Genghis Khan
Sample examined the Y chromosomes of 5,000 Asian men from 127 populations
Historical nomadic and mobile populations allowed for Y chromosomes to be spread far and wide
Geneticists from the University of Leicester have discovered that millions of modern Asian men are descended from 11 powerful dynastic leaders who lived up to 4,000 years ago - including Mongolian warlord Genghis Khan.
The study, which is funded by the Wellcome Trust and published in ...
Males that mate more often are more insecure about their social status than those mating less, according to new research on the behaviour of burying beetles.
The study, published in the journal Evolution, provides new evidence that the social sensitivity of male behaviour is linked to how often male beetles mate.
Male burying beetles actively compete with each other for access to breeding resources such as dead mice, and when they find a suitable carcass will emit pheromones as a signal to attract females. But the emission of pheromones may also attract other males, ...
BUFFALO, N.Y. - Although some children emerge from cold and neglectful family environments as adults with high self-esteem, a new University at Buffalo study suggests these people may still be at a relative disadvantage in life, with a foggier sense of who they are.
On the other hand, adults with low self-esteem who grew up in the same type of negative environment actually have relatively high self-clarity, according to the study's findings.
"Our findings show that even those people who manage to get out of that relatively negative time and view themselves as good, worthwhile ...
Berkeley -- When University of California, Berkeley, bioengineers say they are holding their hearts in the palms of their hands, they are not talking about emotional vulnerability.
Instead, the research team led by bioengineering professor Kevin Healy is presenting a network of pulsating cardiac muscle cells housed in an inch-long silicone device that effectively models human heart tissue, and they have demonstrated the viability of this system as a drug-screening tool by testing it with cardiovascular medications.
This organ-on-a-chip, reported in a study to be published ...
Chestnut Hill, MA (March 9th, 2015): From "Got Milk?" to "What's in your wallet?" to "Are you a Mac or a PC?" promotional phrases consisting of a simple question have proven to be quite effective, but are they more effective than a simple statement? That depends. Henrik Hagtvedt, Ph.D., a Marketing professor at the Carroll School of Management at Boston College, has just finished investigating what happens when you replace a period with a question mark, or vice versa, and how that affects whether a consumer makes a purchase.
"I've long been interested in ambiguity and ...
This news release is available in Spanish. Working in a physically demanding job, having high blood pressure, and taking multiple medications are among health risks that may undermine a man's fertility, according to a study by researchers at the National Institutes of Health and Stanford University, Stanford, California. The study is the first to examine the relationships between workplace exertion, health, and semen quality as men are trying to conceive. The results were published online in Fertility and Sterility.
"Nearly 15 percent of U.S. couples do not become ...
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results indicate that clinicians should take a complete family history of all cancers--even those in family members of the opposite sex--to help assess a patient's risk of developing cancer.
Evidence suggests that the risk of developing breast and prostate cancer is increased among individuals with a family ...
San Diego, CA--In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.
"Sunitinib can potentially be used as an effective adjunctive treatment in patients with advanced differentiated thyroid cancer," said Principal Investigator Kenneth Burman, MD, Chief of Endocrine at MedStar Washington Hospital Center, Washington, ...
